Ovid Therapeutics (OVID) Change in Accured Expenses (2016 - 2026)

Ovid Therapeutics has reported Change in Accured Expenses for 11 years, with the latest figure at -$1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 140100.0% year-over-year to -$1.4 million; the trailing twelve-month figure through Mar 2026 stood at -$2.5 million (down 226.75% YoY), and the FY2025 full-year result was -$1.1 million, down 98.88% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.4 million, down from $2.1 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $4.1 million in Q2 2024, with the low at -$3.4 million in Q2 2022.
• Historically, Change in Accured Expenses has averaged -$244270.9 across 5 years, with a median of -$1000.0 in 2025.
• Annual changes were most pronounced in 2025 — Change in Accured Expenses jumped 229.55% — and 2026, when it sank 140100.0%.
• Ovid Therapeutics' Change in Accured Expenses stood at -$1.2 million in 2022, then jumped by 125.36% to $303000.0 in 2023, then plunged by 622.77% to -$1.6 million in 2024, then jumped by 229.55% to $2.1 million in 2025, then slumped by 168.32% to -$1.4 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.4 million (Q1 2026), $2.1 million (Q4 2025), and $27000.0 (Q3 2025), per Business Quant data.